The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     
9 pts

Opinion on  Forest Laboratories Inc (FRX)     Sector: Healthcare  >  Industry: Biotechnology & Drugs
FDA Action Heats Up Before Year-End

Oct 21, 2008 01:31 AM GMT
Mikerun
Return Risk
+1.04% LOW
Principal

FDA Action Heats Up Before Year-End


The accompanying table presents an updated calendar of expected FDA decision dates and advisory committee [FDAC] meetings expected to impact the price of underlying biotech and pharma stocks. Genzyme (GENZ) faces a FDAC tomorrow (10/21) for its pending BLA for Myozyme manufactured at the 2,000L bioreactor scale. Also, Discovery Labs (DSCO) submitted its complete response to the FDA last Friday to address an approvable ruling for Surfaxin back in May and insiders continue to buy the stock. DSCO expects the FDA to rule on Surfaxin as a Class I review (60-day) rather than the longer Class II period of six months with an official response due by the agency on 10/31/08. Finally, Cypress Bio (CYPB) and Forest Labs (FRX) announced that the FDA would delay its decision on milnacipran as a treatment for fibromyalgia, but the agency stated the matter should be resolved in "a matter of weeks" -- implying there are no major deficiencies in the application.


FRX:  This call was made on 10/21/08 @ $24.74
Rating:   Positive   $24.74 (10/21/08)
Closed:   11/07/2008 @ $23.494 (-5.04% in 17 days)


Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 21.10 +34.57% 370
2 18.14 +68.57% 207
3 17.66 +25.68% 53
4 13.47 +14.32% 61
5 12.13 +77.15% 34


POPULAR STOCKS
Symbol Company Name Sentiment

TODAY'S HEADLINES

TODAY'S TOP PICKS

 
Forest Laboratories Inc (FRX)
   SocialPicks Sentiment:   

   This Quarter's Sentiment:
All:
86.0%
Top:
100.0%




Latest Picks by Mike Havrilla
Symbol SP Sentiment Rating Return Since
IMUC N/A Positive n/a 11/09/09
EXAS Positive +3.80% 11/07/09
NFES N/A Positive n/a 11/07/09
ESALY N/A Negative n/a 11/04/09
PFE Negative -3.72% 11/04/09

View All >
   
Mike Havrilla previously rated FRX
Positive +23.07% Trading the Trials: Cytori and Cypress Bio
12/09/2008
9
Positive +20.32% Updated FDA Calendar of 75 Decision Dates
11/21/2008
9
Positive -17.04% A Backlog of Decisions is Building at the FDA
11/07/2008
9
Positive -15.07% FDA Decision Date Calendar Through January 2009
09/21/2008
3
Positive +1.60% Milnacipran Phase 3 Results and FDA Decision Should Move Forest Labs Off Lows
09/13/2008
3





IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch